CDK4 and neoplasm: Previous studies have documented the significant tumour‐regressive effects of fulvestrant and palbociclib/ribociclib on ER‐positive breast cancer (Figure 6D).[39] Ribociclib and palbociclib are both CDK4/6 inhibitors with similar mechanisms of action and effects, making them clinically applicable for the treatment of ER‐positive breast cancer.[39, 40] This result strongly supports the credibility of our predicted drug combinations with fulvestrant or GDC0810.